This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
“Not surprising…[is] Gilead’s move to stop working to improve on its suite of current hep C remedies, which already offer impressively high cure rates”
Another quarter, another slump for Gilead’s hepatitis C franchise. The one-time powerhouses Sovaldi and Harvoni have fallen victim to competition and payer discounting, with sales plummeting 31% for the quarter.
Gilead’s hep C top line got some help from inventory stocking and one-time revenue in other quarters. Its HIV meds beat analyst estimates by 10%-plus, and overall sales weren’t quite as bad as forecast. But not surprisingly, market-watchers zeroed in on Gilead’s hep C shortfalls–and the company’s lack of a quick solution, including some sort of big M&A move.
Indeed, the hep C sales pain was more intense than market-watchers had expected. HCV revenue came in below some analyst estimates by a double-digit margin, and lower than consensus by 3%. And that’s despite new sales from the recent rollout Epclusa, a regimen that spans all hep C genotypes.